Sign In
Buy CARA
$5.32
+0 (+0%)
At Close: Jul 14, 2025
Cara Therapeutics (CARA) Receives a Buy from Needham
03:58pm, Tuesday, 21'st Apr 2020
In a report released today, Alan Carr from Needham assigned a Buy rating to Cara Therapeutics (CARA), with a price target of $35.00. The company's shares
Cara Therapeutics (CARA) Receives a Buy from Needham
03:58pm, Tuesday, 21'st Apr 2020
In a report released today, Alan Carr from Needham assigned a Buy rating to Cara Therapeutics (CARA – Research Report),
Cara Therapeutics (CARA) Gets a Buy Rating from H.C. Wainwright
03:43pm, Tuesday, 21'st Apr 2020
H.C. Wainwright analyst Oren Livnat maintained a Buy rating on Cara Therapeutics (CARA) today and set a price target of $33.00. The company's shares
Cara Therapeutics (CARA) Gets a Buy Rating from H.C. Wainwright
03:43pm, Tuesday, 21'st Apr 2020
H.C. Wainwright analyst Oren Livnat maintained a Buy rating on Cara Therapeutics (CARA – Research Report) today and set a
The Daily Biotech Pulse: Applied DNA Begins Validating COVID-19 Test, Cara's Positive Readout, Novan Explores Strategic Alternatives
12:19pm, Tuesday, 21'st Apr 2020
Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs April 20) * Abbott Laboratories (NYSE: ABT) * Acceleron Phar
Cara Therapeutics' Shares March Higher, Can It Continue?
12:07pm, Tuesday, 21'st Apr 2020
As of late, it has definitely been a great time to be an investor in Cara Therapeutics.
Cara Therapeutics' Shares March Higher, Can It Continue?
12:07pm, Tuesday, 21'st Apr 2020
As of late, it has definitely been a great time to be an investor in Cara Therapeutics.
Cara's Korsuva successful in second late-stage study
10:38am, Tuesday, 21'st Apr 2020
Cara Therapeutics (NASDAQ:CARA) and licensee Vifor Fresenius Medical Care Renal Pharma announce positive results from a Phase 3 clinical trial, KALM-2, evaluating Korsuva (CR845/difelikefalin) Injecti
Statistically significant improvement in primary endpoint of proportion of patients with three point or greater reduction in mean worst itching intensity NRS score vs. placebo (p=0.02) Statisticall…
Statistically significant improvement in primary endpoint of proportion of patients with three point or greater reduction in mean Worst Itching Intensity NRS score vs. placebo.
Regulatory News:
The Daily Biotech Pulse: Applied DNA Begins Validating COVID-19 Test, Cara's Positive Readout, Novan Explores Strategic Alternatives
12:00am, Tuesday, 21'st Apr 2020
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks that hit 52-week highs April 20)
Abbott Laboratories (NYSE...
Postoperative Nausea & Vomiting (PONV) 2017-2028: Market Insights, Epidemiology and Forecast - ResearchAndMarkets.com
01:22pm, Monday, 20'th Apr 2020
The "Postoperative Nausea & Vomiting (PONV) 2017-2028: Market Insights, Epidemiology and Forecast" drug pipelines has been added to ResearchAndMarkets.com's offering.
Alliancebernstein L.P. Raises Stake in Cara Therapeutics Inc (NASDAQ:CARA)
09:14am, Sunday, 19'th Apr 2020
Alliancebernstein L.P. lifted its stake in shares of Cara Therapeutics Inc (NASDAQ:CARA) by 4.8% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchan
Bank of New York Mellon Corp Sells 20,380 Shares of Cara Therapeutics Inc (NASDAQ:CARA)
08:24am, Sunday, 19'th Apr 2020
Bank of New York Mellon Corp decreased its stake in shares of Cara Therapeutics Inc (NASDAQ:CARA) by 10.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchan
